Simvastatin inhibits C-reactive protein-induced pro-inflammatory changes in endothelial cells by decreasing mevalonate pathway products

Yao J. Liang, Kou G. Shyu, Bao W. Wang, Ling Ping Lai

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

Objectives: The effects of HMG-CoA reductase inhibitors on C-reactive protein (CRP)-induced pro-inflammatory changes in endothelial cells remain unclear. We tested the hypothesis that simvastatin inhibited CRP-induced pro-inflammatory changes in endothelial cells by decreasing mevalonate pathway products. Methods: Human umbilical vein endothelial cells were incubated with CRP and measurement of CD32, nuclear factor κB (NF-κB) activation, vascular cell adhesion molecule-1 expression and monocyte adhesion assay were performed. The effects of simvastatin, siRNA against CD32 (siCD32) and mevalonate pathway products were also examined. Results: Pre-treatment with simvastatin significantly attenuated the CRP-induced CD32 expression and NF-κB activation in human umbilical vein endothelial cells. Simvastatin also decreased CRP-induced vascular cell adhesion molecule-1 expression and reduced monocyte adhesion on endothelial cells. The inhibitory effects of simvastatin were significantly reversed by adding mevalonate and geranylgeranyl pyrophosphate (GGPP), but not by adding farnesyl pyrophosphate. Pre-treatment with siCD32 also decreased CRP-induced CD32 expression and inhibitor of κB degradation. However, neither mevalonate nor GGPP reversed the effects of siCD32. Conclusions: CRP-induced CD32 expression and NF-κB activation were attenuated by simvastatin. A decrease in mevalonate and subsequent GGPP contributes to the inhibitory effects of simvastatin. These findings may provide an explanation of using statins on patients with high serum CRP levels.

Original languageEnglish
Pages (from-to)182-190
Number of pages9
JournalCardiology
Volume110
Issue number3
DOIs
Publication statusPublished - Jun 2008

Fingerprint

Mevalonic Acid
Simvastatin
C-Reactive Protein
Endothelial Cells
Small Interfering RNA
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Vascular Cell Adhesion Molecule-1
Human Umbilical Vein Endothelial Cells
Monocytes
Blood Proteins
Therapeutics

Keywords

  • C-reactive protein
  • Lipid metabolism
  • Receptors
  • Statins
  • Vascular cell adhesion molecule-1

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Simvastatin inhibits C-reactive protein-induced pro-inflammatory changes in endothelial cells by decreasing mevalonate pathway products. / Liang, Yao J.; Shyu, Kou G.; Wang, Bao W.; Lai, Ling Ping.

In: Cardiology, Vol. 110, No. 3, 06.2008, p. 182-190.

Research output: Contribution to journalArticle

Liang, Yao J. ; Shyu, Kou G. ; Wang, Bao W. ; Lai, Ling Ping. / Simvastatin inhibits C-reactive protein-induced pro-inflammatory changes in endothelial cells by decreasing mevalonate pathway products. In: Cardiology. 2008 ; Vol. 110, No. 3. pp. 182-190.
@article{47cb4355d0864e87a91782c1c411e0e2,
title = "Simvastatin inhibits C-reactive protein-induced pro-inflammatory changes in endothelial cells by decreasing mevalonate pathway products",
abstract = "Objectives: The effects of HMG-CoA reductase inhibitors on C-reactive protein (CRP)-induced pro-inflammatory changes in endothelial cells remain unclear. We tested the hypothesis that simvastatin inhibited CRP-induced pro-inflammatory changes in endothelial cells by decreasing mevalonate pathway products. Methods: Human umbilical vein endothelial cells were incubated with CRP and measurement of CD32, nuclear factor κB (NF-κB) activation, vascular cell adhesion molecule-1 expression and monocyte adhesion assay were performed. The effects of simvastatin, siRNA against CD32 (siCD32) and mevalonate pathway products were also examined. Results: Pre-treatment with simvastatin significantly attenuated the CRP-induced CD32 expression and NF-κB activation in human umbilical vein endothelial cells. Simvastatin also decreased CRP-induced vascular cell adhesion molecule-1 expression and reduced monocyte adhesion on endothelial cells. The inhibitory effects of simvastatin were significantly reversed by adding mevalonate and geranylgeranyl pyrophosphate (GGPP), but not by adding farnesyl pyrophosphate. Pre-treatment with siCD32 also decreased CRP-induced CD32 expression and inhibitor of κB degradation. However, neither mevalonate nor GGPP reversed the effects of siCD32. Conclusions: CRP-induced CD32 expression and NF-κB activation were attenuated by simvastatin. A decrease in mevalonate and subsequent GGPP contributes to the inhibitory effects of simvastatin. These findings may provide an explanation of using statins on patients with high serum CRP levels.",
keywords = "C-reactive protein, Lipid metabolism, Receptors, Statins, Vascular cell adhesion molecule-1",
author = "Liang, {Yao J.} and Shyu, {Kou G.} and Wang, {Bao W.} and Lai, {Ling Ping}",
year = "2008",
month = "6",
doi = "10.1159/000111928",
language = "English",
volume = "110",
pages = "182--190",
journal = "Cardiology",
issn = "0008-6312",
publisher = "S. Karger AG",
number = "3",

}

TY - JOUR

T1 - Simvastatin inhibits C-reactive protein-induced pro-inflammatory changes in endothelial cells by decreasing mevalonate pathway products

AU - Liang, Yao J.

AU - Shyu, Kou G.

AU - Wang, Bao W.

AU - Lai, Ling Ping

PY - 2008/6

Y1 - 2008/6

N2 - Objectives: The effects of HMG-CoA reductase inhibitors on C-reactive protein (CRP)-induced pro-inflammatory changes in endothelial cells remain unclear. We tested the hypothesis that simvastatin inhibited CRP-induced pro-inflammatory changes in endothelial cells by decreasing mevalonate pathway products. Methods: Human umbilical vein endothelial cells were incubated with CRP and measurement of CD32, nuclear factor κB (NF-κB) activation, vascular cell adhesion molecule-1 expression and monocyte adhesion assay were performed. The effects of simvastatin, siRNA against CD32 (siCD32) and mevalonate pathway products were also examined. Results: Pre-treatment with simvastatin significantly attenuated the CRP-induced CD32 expression and NF-κB activation in human umbilical vein endothelial cells. Simvastatin also decreased CRP-induced vascular cell adhesion molecule-1 expression and reduced monocyte adhesion on endothelial cells. The inhibitory effects of simvastatin were significantly reversed by adding mevalonate and geranylgeranyl pyrophosphate (GGPP), but not by adding farnesyl pyrophosphate. Pre-treatment with siCD32 also decreased CRP-induced CD32 expression and inhibitor of κB degradation. However, neither mevalonate nor GGPP reversed the effects of siCD32. Conclusions: CRP-induced CD32 expression and NF-κB activation were attenuated by simvastatin. A decrease in mevalonate and subsequent GGPP contributes to the inhibitory effects of simvastatin. These findings may provide an explanation of using statins on patients with high serum CRP levels.

AB - Objectives: The effects of HMG-CoA reductase inhibitors on C-reactive protein (CRP)-induced pro-inflammatory changes in endothelial cells remain unclear. We tested the hypothesis that simvastatin inhibited CRP-induced pro-inflammatory changes in endothelial cells by decreasing mevalonate pathway products. Methods: Human umbilical vein endothelial cells were incubated with CRP and measurement of CD32, nuclear factor κB (NF-κB) activation, vascular cell adhesion molecule-1 expression and monocyte adhesion assay were performed. The effects of simvastatin, siRNA against CD32 (siCD32) and mevalonate pathway products were also examined. Results: Pre-treatment with simvastatin significantly attenuated the CRP-induced CD32 expression and NF-κB activation in human umbilical vein endothelial cells. Simvastatin also decreased CRP-induced vascular cell adhesion molecule-1 expression and reduced monocyte adhesion on endothelial cells. The inhibitory effects of simvastatin were significantly reversed by adding mevalonate and geranylgeranyl pyrophosphate (GGPP), but not by adding farnesyl pyrophosphate. Pre-treatment with siCD32 also decreased CRP-induced CD32 expression and inhibitor of κB degradation. However, neither mevalonate nor GGPP reversed the effects of siCD32. Conclusions: CRP-induced CD32 expression and NF-κB activation were attenuated by simvastatin. A decrease in mevalonate and subsequent GGPP contributes to the inhibitory effects of simvastatin. These findings may provide an explanation of using statins on patients with high serum CRP levels.

KW - C-reactive protein

KW - Lipid metabolism

KW - Receptors

KW - Statins

KW - Vascular cell adhesion molecule-1

UR - http://www.scopus.com/inward/record.url?scp=44849126759&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=44849126759&partnerID=8YFLogxK

U2 - 10.1159/000111928

DO - 10.1159/000111928

M3 - Article

C2 - 18057884

AN - SCOPUS:44849126759

VL - 110

SP - 182

EP - 190

JO - Cardiology

JF - Cardiology

SN - 0008-6312

IS - 3

ER -